Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- GSK to Supply Tenozet by Imports from Gilead
December 15, 2015
- Astellas Joins Hands with US Biopharma Bellicum on Cancer Cell Therapy
December 14, 2015
- Novartis Submits Business Improvement Plan over ADR Reporting Delays
December 14, 2015
- ASKA to Launch Authorized Generics of Unisia in March
December 14, 2015
- Ono Files Opdivo for Kidney Cancer, Third Indication in Japan
December 14, 2015
- Mundipharma to Link Up with Shionogi on Isodine Brand, Dissolve Ties with Meiji Seika Pharma
December 11, 2015
- M&As among Generic Makers Would Reap No Benefits: Sawai President
December 11, 2015
- Sumitomo Dainippon to Launch 3 Pivotal Trials for Napabucasin in FY2015, Postpone BBI503 Program
December 10, 2015
- Sumitomo Dainippon to Begin Lurasidone PIII within FY2015, 3rd Attempt for Schizophrenia Indication
December 10, 2015
- Mitsubishi Chemical Holdings to Invest in New Production Facilities for Drugs and Vaccines
December 10, 2015
- Stephen Hitchcock Tapped as Head of Pharma Research at Takeda
December 9, 2015
- Takeda Ties Up with US Biotech Cour on Immune Modulating Therapies
December 9, 2015
- Ethical Drug Sales Zoom 10.7% in October: Crecon Report
December 9, 2015
- Mega Mergers Not the Best Way to Get Drug Discovery Prowess: Astellas President
December 9, 2015
- Sovaldi Top-Prescribed Drug at Japanese Acute Hospitals in July-Sept.
December 8, 2015
- Belsomra Most Promoted Drug for GPs for 4 Months Running: Anterio
December 8, 2015
- Otsuka Seeks Japan Approval of Abilify for Juvenile Autism-Linked Excitability
December 8, 2015
- MM Treatment Ixazomib Extends PFS in PIII: Takeda
December 8, 2015
- Nothing Decided for Japan Market over Pfizer’s Allergan Acquisition: Umeda
December 7, 2015
- Global PII for Pediatric X-Linked Hypophosphatemia Yields Positive Data: Kyowa Kirin
December 7, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…